REGENERX (RGN) Reports Study Data on Tb4 Drug Candidates
More News related to RGN
- Researchers Report Elevated Levels of Tb4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver Failure
- Researchers Report that Tb4 Increases Skeletal Muscle and May Have a Role in the Treatment of Duchenne Muscular Dystrophy
- Regenerx Biopharma (RGN) Moving Maryland HQ
- RegeneRx Biopharmaceuticals, Inc. Moving to New Corporate Office Space
- Morning Movers 01/12: ZRBA, EFOI, VLNC, CDII, YRCW, ERI Higher; GAP, ATSI, MFLX, CACH Lower
More News related to FDA
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
REGENERX BIOPHARMACEUTICALS, INC. (Amex: RGN) reported on several clinical studies with Thymosin beta 4 (Tb4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.
More from Release
Related Categories
FDAStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
